1 Min Read
Dec 7 (Reuters) - Compugen Ltd:
* Compugen-In process of developing therapeutic antibody for cgen-15137/tigit, and expect to select lead antibody for this target by end of Q1 of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.